Bruker (NASDAQ:BRKR) Given New $60.00 Price Target at Jefferies Financial Group

Key Points

• Jefferies Financial Group has lowered its price target for Bruker from $70.00 to $60.00, while maintaining a "buy" rating, suggesting a potential upside of 72.81% from the company's previous close.
• Bruker's stock price dropped 8.6% to $34.72 during trading, with a market capitalization of $5.26 billion and a current ratio of 1.57.
• The company's latest quarterly earnings revealed an EPS of $0.32, missing expectations, with revenue of $797.40 million, down 0.4% year-over-year.

Bruker (NASDAQ:BRKR - Get Free Report) had its target price dropped by analysts at Jefferies Financial Group from $70.00 to $60.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the medical research company's stock. Jefferies Financial Group's price objective would suggest a potential upside of 72.81% from the company's previous close.

Other research analysts have also issued reports about the stock. The Goldman Sachs Group decreased their price objective on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Wells Fargo & Company decreased their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Barclays cut their price objective on shares of Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Stifel Nicolaus cut their price objective on shares of Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a research report on Thursday, May 8th. Finally, UBS Group dropped their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $53.60.

Bruker Stock Down 8.6%

NASDAQ BRKR traded down $3.27 during trading hours on Monday, hitting $34.72. The company had a trading volume of 8,149,176 shares, compared to its average volume of 2,385,735. Bruker has a fifty-two week low of $32.07 and a fifty-two week high of $72.94. The company has a market capitalization of $5.26 billion, a price-to-earnings ratio of 66.77, a P/E/G ratio of 2.56 and a beta of 1.16. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74. The firm's 50 day moving average is $39.94 and its 200 day moving average is $43.35.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.11). Bruker had a return on equity of 19.47% and a net margin of 2.31%. The firm had revenue of $797.40 million for the quarter, compared to analysts' expectations of $811.17 million. During the same period last year, the firm earned $0.52 EPS. The business's quarterly revenue was down .4% on a year-over-year basis. Sell-side analysts anticipate that Bruker will post 2.69 earnings per share for the current fiscal year.

Insider Activity at Bruker

In other news, CEO Frank H. Laukien acquired 2,608 shares of the stock in a transaction dated Friday, June 6th. The stock was bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the purchase, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This represents a 0.01% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 27.30% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BRKR. Teacher Retirement System of Texas grew its position in shares of Bruker by 5.1% during the 1st quarter. Teacher Retirement System of Texas now owns 29,045 shares of the medical research company's stock worth $1,212,000 after buying an additional 1,422 shares during the period. Fifth Third Bancorp lifted its stake in Bruker by 54.2% during the 1st quarter. Fifth Third Bancorp now owns 1,109 shares of the medical research company's stock valued at $46,000 after acquiring an additional 390 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Bruker by 81.2% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 29,826 shares of the medical research company's stock valued at $1,245,000 after acquiring an additional 13,367 shares in the last quarter. OneDigital Investment Advisors LLC raised its stake in shares of Bruker by 38.0% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,522 shares of the medical research company's stock worth $230,000 after purchasing an additional 1,520 shares during the period. Finally, Sterling Capital Management LLC raised its stake in shares of Bruker by 29.0% during the 4th quarter. Sterling Capital Management LLC now owns 3,514 shares of the medical research company's stock worth $206,000 after purchasing an additional 791 shares during the period. Institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.